XENE's Quality Score rose 3 points on Fri, Nov 6, to -1. It closed near its high of the day (2 chart checks started).
Follow XENE's trial news. Pro members can get an alert when Xenon Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 39% in 3 months while the S&P 500 fell 5%.
−2Long-term trend
| Holding it back | 26.2% more shares than a year ago |
| Latest filing | 10-Q, Aug 6 |
ReportReports today, after the close. Every 3 months, a company tells everyone how much it sold and earned. It fell after 3 of its last 4 reports, -2.4% on average. Past reports ›
Tue Nov 10: Guggenheim 3rd Annual Global…Investor conference · date confirmed.
3 more dates ahead: conferences, for Pro members.
After its last 4 reports it closed -2.4% on average, higher 1 of 4 times.
About 14 quarters
CFO Thomas Patrick Kelly bought 15,000 shares on Sep 30. 12 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
XENE is #155 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 155 |
Net income over four quarters: XENE -$409M, AUPH $314M, ABCL -$165M, ZLAB -$188M.
Reports Mon Nov 9, after the close (today). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The increase in net loss for the period was primarily attributable to lower revenue from the collaboration with Neurocrine Biosciences, higher research and development expenses driven by the azetukalner and pain programs and higher personnel-related costs, higher general and administrative expenses driven by higher personnel-related costs and professional and consulting fees, partially offset by higher interest income.”
XENE's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“We also remain focused on broadening azetukalner’s opportunity to neuropsychiatry and expect topline Phase 3 X-NOVA2 data in the first half of 2027.”
From its results filing (SEC filing · Aug 6)
Its share count grew 18% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Aug 6, 2026 | -2.4% | -1.8% | -0.5% |
| May 7, 2026 | +0.2% | +0.8% | 0.0% |
| Feb 26, 2026 | +1.1% | -3.8% | -6.4% |
Sales grew in two of the last six years, to $7.5M in 2025. It lost money in each of the seven years.
RSI 52.6, MACD above signal, below both averages. Not scored.
2 insiders bought $1.7M across 2 filings, and one insider sold $641K across 1 filing, in the last 6 months. The newest:
Officers and directors with a Form 4 in the last 12 months.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
“The biotechnology and pharmaceutical industries are highly competitive and are characterized by rapidly advancing technologies and a strong emphasis on proprietary products.”
XENE scores -1 today, which Breakaway calls Poor. It is #155 of 281 in Biotech by Quality Score, with 3 of 14 chart checks firing. Down 39% in 3 months while the S&P 500 fell 5%. Cash lasts about 14 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
XENE scores -1 today, which Breakaway calls Poor (below zero). That is #155 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind XENE's -1.
2 insiders bought $1.7M across 2 filings, and one insider sold $641K across 1 filing, in the last 6 months. The newest is Ian Mortimer, President & CEO, who bought $1.1M on Sep 30. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.